Wellgistics Health (WGRX) announced that its wholly owned subsidiary, Wellgistics has entered into an agreement with Tollo Health to market Tollo’s emerging proprietary suite of novel medical food products for GLP-1 treatment-related side effects, including muscle loss and Long COVID to pharmacies. Tollo is bringing to market novel, proprietary medical food products to address muscle loss and gut discomfort associated with GLP-1 drug use, and persistent viral infection, gut discomfort, sarcopenia, immune dysregulation, cellular senescence, endothelial damage and general nutritional support for patients with Long COVID. Tollo’s first marketed product is Galectovid, a proprietary medical food for the dietary management of Galectin-1 & 3 associated viral infections.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.